KGK Sciences And Halucenex Sign Contract For Phase II Clinical Trial On Psilocybin For PTSD
KGK Sciences And Halucenex Sign Contract For Phase II Clinical Trial On Psilocybin For PTSD
For its part, Wellbeing Digital is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics. Its subsidiary KGK is a North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products since 1997. KGK Sciences Inc., a subsidiary company of psychedelics healthcare researcher and provider Wellbeing Digital Sciences Inc. (OTC:KONEF), has entered into a research services agreement with Halucenex Life Sciences Inc., a psychedelics subsidiary of Creso Pharma (OTC:COPHF) developing phase 2 clinical trials to test the efficacy of psilocybin on treatment-resistant post traumatic stress disorder (PTSD).
KGK Science Inc.，迷幻醫療保健研究和提供商的子公司幸福數字科學公司(場外交易代碼：KONEF)，已與以下公司簽訂研究服務協議Halucenex生命科學公司。，迷幻藥的子公司Creso Pharma(場外交易代碼：COPHF)開發第二階段臨牀試驗以測試裸蓋菇素治療難治性創傷後應激障礙的療效觀察
The deal involves KGK performing research services, including the development of the clinical trial protocol, preparations towards the phase 2 trials, data management and validation, statistical analysis and drafting of the final report.
這筆交易涉及KGK提供研究服務包括制定臨牀試驗方案、籌備第二階段試驗、數據管理和驗證、統計分析和起草最終報告。
Creso Pharma usually works with cannabis, bringing pharmaceutical expertise and methodological rigor to their high-quality, GMP products, offering from cannabis to hemp-derived therapeutic, nutraceutical, and lifestyle products with wide patient and consumer reach for human and animal health.
Creso Pharma通常用於大麻，為其高質量的GMP產品帶來製藥專業知識和方法上的嚴謹，提供從大麻到大麻衍生的治療性、保健品和生活方式產品，為人類和動物健康提供廣泛的患者和消費者接觸。
For its part, Wellbeing Digital is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics. Its subsidiary KGK is a North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products since 1997.
就其本身而言，WellBeing Digital是一家以證據為基礎的精神保健公司，專注於開發和實施創新的臨牀治療解決方案，包括迷幻藥物和數字療法。其子公司KGK是一家總部設在安大略省倫敦的北美合同研究機構，自1997年以來主要提供高質量的臨牀研究試驗，重點是營養食品和新興保健產品。
As Wellbeing and KGK's CEO Najla Guthrie stated: "Over the past 25 years, we have successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies that move products efficiently into the global markets. This marks an important step in moving the industry that much closer to creating alternative medicines for a growing population base."
AS福祉和KGK的首席執行官納吉拉·格思裏聲明説：“在過去的25年裏，我們成功地幫助了數百家公司進行了定製設計的臨牀試驗，並聲稱實施了有效地將產品推向全球市場的證實策略。這標誌着該行業朝着為不斷增長的人口基礎創造替代藥物邁出了重要的一步。”
On his behalf, Halucenex CEO and founder Bill Flemming added: "KGK is a leading contract research organization, offering high-quality clinical research trials and expert regulatory support for the nutraceutical, cannabinoid, hemp and psychedelic industries. We are confident that KGK's role will enable us to make considerable progress towards creating alternative treatment solutions to current pharmacological interventions."
以他的名義，Halucenex首席執行官兼創始人比爾·弗萊明KGK是一家領先的合同研究組織，為營養食品、大麻、大麻和迷幻藥行業提供高質量的臨牀研究試驗和專家監管支持。我們相信，KGK的作用將使我們在創造替代治療解決方案方面取得相當大的進展，以取代目前的藥物幹預。
Photo Courtesy of Geralt Sergei Tokmakov on Pixabay.
照片由Geralt Sergei Tokmakov在Pixabay上提供。
